Hemogenyx Pharmaceuticals PLC AGM Statement (6267Y)
December 07 2017 - 1:00AM
UK Regulatory
TIDMHEMO
RNS Number : 6267Y
Hemogenyx Pharmaceuticals PLC
07 December 2017
This announcement contains inside information which, prior to
its disclosure, was inside information for the purposes of the
Market Abuse Regulation (Article 7 of Regulation (EU) No
596/2014.
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
AGM Statement
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, will hold its Annual General Meeting today at 10:00am at
the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London
EC4M 7RD.
Ahead of the formal business of the AGM, the Board will provide
the following strategic update on its activities, technology and
products following its successful IPO and Admission to the main
market of the London Stock Exchange (LSE) on 5 October 2017:
Laboratory activities are progressing well and to plan, with
capacity expanded and the Company's modest scientific recruitment
programme almost complete. Activities are focused on working with
LakePharma Inc. and Oxford University, its recently announced
collaborator, to help progress two distinct but complementary novel
proprietary therapies, CDX (a novel bispecific antibody) and HuPHEC
(a novel cell therapy), which aim to change the way in which bone
marrow/hematopoietic stem cell transplants (BMT/HSCT) are performed
and strongly improve their efficacy.
The appointment of LakePharma provides a strategic partner to
help accelerate development of the Company's CDX bispecific
antibody (an immunotherapy-class treatment) for patient
'conditioning', the first step required in preparing patients for a
BMT. The Company aims to replace current toxic conditioning
modalities, which include radiation and chemotherapy, thereby
increasing the number of candidate patients for BMT and allowing a
greater proportion of these to be successfully conditioned for the
subsequent bone marrow transplant. LakePharma, the largest US-based
biologics contract research organisation, brings integrated
antibody engineering and bioproduction expertise to allow Hemogenyx
to advance its CDX product through the necessary preclinical stages
to potentially be ready to enter the clinic within 16 months. To
date, work is progressing successfully toward the Company's
immediate goal of submitting an IND application to the US Food and
Drug Administration.
As announced in October, Hemogenyx has engaged LakePharma for
the development and manufacture of CDX antibodies for Hemogenyx's
conditioning product, a major step in the pre-clinical development
of this product using the expertise and validated technology of
LakePharma, the largest US-based biologics contract research
organisation.
The collaboration with the University of Oxford and Professor
Jagdeep Nanchahal's team at the Kennedy Institute of Rheumatology
aims to examine the action of certain biological molecules on
stimulating transplanted blood stem cells to transition - faster
and more effectively - from dormant to activated state to produce
healthy blood cells. The Company anticipates that the resulting
increase in the number of activated blood stem cells will result in
the accelerated engraftment of hematopoietic stem cells when
transplanted in a BMT. This work could lead to additional uses of
the Company's HuPHEC product. HuPHECs, or Human Post-natal
Hemogenic Endothelial Cells, are Hemogenyx's proprietary source of
blood stem cells that are able to generate cancer-free,
patient-matched blood stem cells and represent the basis for the
Company's novel cell therapy. A successful outcome of the work with
Oxford University has the potential to significantly improve the
efficiency and safety of future bone marrow transplants.
In addition, Hemogenyx has expanded its material transfer
agreement with a major US research university, under which
Hemogenyx has secured a reliable high-quality supply of human
tissues for the development of both its CDX bispecific antibody
product and its HuPHEC cell therapy product.
The Board of Directors are evaluating additional collaborations
with a range of potential academic and corporate partners, and hope
to be in a position to update shareholders on progress in due
course.
In summary, the Directors believe that the Company is
well-advanced on the planned development steps that were announced
on its Admission and are looking forward to the next 12 months with
great confidence and high expectations.
Commenting on the Company's progress thus far, Dr. Vladislav
Sandler, CEO of Hemogenyx, said: "We believe the products we are
developing should greatly reduce the dangers of patient
conditioning procedures and create a new form of blood stem cell
transplantation which, if successful, would significantly enhance
the long-term success of bone marrow transplants. The appointment
of LakePharma and collaboration with Oxford University represent
significant steps towards our strategic goal of applying novel
technologies to transform the lives of bone marrow transplant
patients. We look forward to keeping shareholders fully abreast of
developments as they occur."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930
Limited
Lucy Williams/Duncan Vasey
Walbrook PR Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMFSIESMFWSEEE
(END) Dow Jones Newswires
December 07, 2017 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024